Publications by authors named "K Notsumata"
Article Synopsis
- The study assessed the effectiveness of serum type 4 collagen 7S (COL4-7S) compared to the Enhanced Liver Fibrosis (ELF) score in detecting liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
- Among 1,368 patients, 794 were analyzed, revealing that both COL4-7S and ELF scores rise with increasing fibrosis, but COL4-7S showed significantly better performance for identifying advanced fibrosis (≥2) especially in diabetic patients.
- Overall, COL4-7S proved to be at least as effective as the ELF score in diagnosing advanced liver disease in MASLD patients.
Article Synopsis
- * The researchers analyzed 41 patients diagnosed with IAAD through AUS and CT scans, comparing them to a group of 205 patients without the condition, discovering significant associations with smoking and fatty liver in those with IAAD.
- * The findings suggest that older patients with risk factors (like fatty liver and smoking) should have regular abdominal aorta monitoring through ultrasonography during health check-ups to catch IAAD early.
Article Synopsis
- The study explores the prevalence of steatotic liver disease (SLD) using the new multisociety consensus nomenclature, identifying its different subtypes such as MASLD and MetALD among 6,530 health check-up participants in Japan.
- Results indicate a 39.5% overall prevalence of SLD, with most cases classified as MASLD, and a small portion showing significant fibrosis as determined by liver stiffness measurement.
- Although the FIB-4 index is convenient for assessing liver fibrosis, its diagnostic performance as a primary screening tool is limited, particularly in the general population, suggesting the need for more effective screening methods.
Background And Aims: The diagnostic performance of the Fibrosis-4 (FIB-4) index and nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) is poor in patients with type 2 diabetes mellitus (T2DM). We determined the usefulness of the Enhanced Liver Fibrosis (ELF) test in patients with T2DM.
Methods: A total of 1228 patients with biopsy-proven NAFLD were enrolled.
Aim: To compare patient characteristics and outcomes between the overall and Japanese populations of GLIMMER.
Methods: GLIMMER was a multicenter, double-blind, randomized, placebo-controlled, Phase IIb study evaluating linerixibat for the treatment of pruritus in patients with primary biliary cholangitis.
Results: In total, 147 patients were randomized in the GLIMMER overall population with 38 patients comprising the Japanese population.